Search research articles

Search research articles

Related Experiment Videos

[Interferon therapy of multiple sclerosis].

¹Nevrologisk avdeling Rikshospitalet, Oslo.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke

|October 16, 1999

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reference values for six-minute walk distance and six-minute walk work in Caucasian adults.

Pulmonology·2023

Same author

Quality of life and sexuality in women with lichen sclerosus: a cross-sectional study.

Clinical and experimental dermatology·2021

Same author

Invited review: Toward a common language in data-driven mastitis detection research.

Journal of dairy science·2021

Same author

Short pulse intense pulsed light versus pulsed dye laser for the treatment of facial redness.

Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology·2020

Same author

Search for Sterile Neutrinos in MINOS and MINOS+ Using a Two-Detector Fit.

Physical review letters·2019

Same author

Impact of Time to Treatment Initiation in Patients with Human Papillomavirus-positive and -negative Oropharyngeal Squamous Cell Carcinoma.

Clinical oncology (Royal College of Radiologists (Great Britain))·2018

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Beta-interferon therapy for multiple sclerosis (MS) modulates the immune system, reducing relapse rates by approximately 30%. While effective, outcomes vary based on disease severity and product, with antibody formation still under investigation.

Area of Science:

Neuroimmunology
Pharmacology

Context:

Beta-interferon (IFN-β) is an established therapy for relapsing-remitting multiple sclerosis (RRMS).
Multiple IFN-β products (IFN-β-1b and IFN-β-1a) are available in Norway via subcutaneous or intramuscular injection.

Purpose:

To review the efficacy and safety of beta-interferon therapy in multiple sclerosis.
To discuss international study results and emerging data on secondary progressive MS (SPMS).

Summary:

IFN-β treatment demonstrates immunomodulatory effects, inhibiting leukocyte proliferation and antigen presentation.
A ~30% reduction in relapse rates is observed for available products.
Variations in disability progression, adverse reactions, and patient outcomes exist, with less affected patients showing better results.

Related Experiment Videos

Neutralizing antibody development during treatment requires further investigation.

Impact:

Beta-interferon therapy offers a significant therapeutic option for managing multiple sclerosis, particularly RRMS.
Expanded indications for IFN-β therapy in MS are anticipated.
Further research is needed to clarify the role of neutralizing antibodies and optimize treatment strategies.